The effect of FK 506 on canine pancreatic islet cell function in beagle dogs.

PubWeight™: 0.86‹?›

🔗 View Article (PMID 1703709)

Published in Transplant Proc on February 01, 1991

Authors

S Strasser1, R Alejandro, C Ricordi, S Todo, D H Mintz

Author Affiliations

1: University of Miami School of Medicine, Diabetes Research Institute, Florida 33101.

Articles by these authors

FK 506 for liver, kidney, and pancreas transplantation. Lancet (1989) 13.70

Cell migration, chimerism, and graft acceptance. Lancet (1992) 12.24

Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatology (1993) 8.76

The many faces of multivisceral transplantation. Surg Gynecol Obstet (1991) 6.89

Long survival in rats after multivisceral versus isolated small-bowel allotransplantation under FK 506. Surgery (1991) 5.92

Abdominal organ cluster transplantation for the treatment of upper abdominal malignancies. Ann Surg (1989) 5.78

Refinements in the surgical technique of liver transplantation. Semin Liver Dis (1985) 5.70

Bone marrow augmentation of donor-cell chimerism in kidney, liver, heart, and pancreas islet transplantation. Lancet (1994) 5.54

Conversion from cyclosporine to FK 506 in liver allograft recipients with cyclosporine-related complications. Transplant Proc (1990) 4.90

A simplified technique for revascularization of homografts of the liver with a variant right hepatic artery from the superior mesenteric artery. Surg Gynecol Obstet (1985) 4.29

Donor cell chimerism permitted by immunosuppressive drugs: a new view of organ transplantation. Immunol Today (1993) 4.29

Heterotopic heart transplantation in the rat receiving FK-506 alone or with cyclosporine. Transplant Proc (1987) 4.21

Pancreatic islet transplantation after upper abdominal exenteration and liver replacement. Lancet (1990) 4.18

Experience in hepatic resection for metastatic colorectal cancer: analysis of clinical and pathologic risk factors. Surgery (1994) 4.16

Orthotopic liver transplantation with preservation of the inferior vena cava. Ann Surg (1989) 4.12

Baboon-to-human liver transplantation. Lancet (1993) 4.01

Replacement of donor lymphoid tissue in small-bowel transplants. Lancet (1991) 3.85

Immunosuppressive effect of FK-506 on in vitro lymphocyte alloactivation: synergism with cyclosporine A. Transplant Proc (1987) 3.73

The insulin gene is transcribed in the human thymus and transcription levels correlated with allelic variation at the INS VNTR-IDDM2 susceptibility locus for type 1 diabetes. Nat Genet (1997) 3.70

Systemic chimerism in human female recipients of male livers. Lancet (1992) 3.63

Transplantation of multiple abdominal viscera. JAMA (1989) 3.59

Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg (1991) 3.57

Canine liver transplantation under Nva2-cyclosporine versus cyclosporine. Transplantation (1986) 3.54

IN VITRO IMMUNOSUPPRESSIVE EFFECTS OF FR 900506 ON HUMAN T LYMPHOCYTE ALLOACTIVATION. Surg Res Commun (1987) 3.46

Selected topics on FK 506, with special references to rescue of extrahepatic whole organ grafts, transplantation of "forbidden organs," side effects, mechanisms, and practical pharmacokinetics. Transplant Proc (1991) 3.40

Chimerism after liver transplantation for type IV glycogen storage disease and type 1 Gaucher's disease. N Engl J Med (1993) 3.36

Kidney transplantation under FK 506 immunosuppression. Transplant Proc (1991) 3.31

Rejection of multivisceral allografts in rats: a sequential analysis with comparison to isolated orthotopic small-bowel and liver grafts. Surgery (1990) 3.18

Liver transplantation before 1 year of age. J Pediatr (1987) 3.15

In Vitro Immunosuppressive Effects of FK506 in Combination With Other Drugs. Transplant Proc (1988) 3.15

The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. Transplantation (1991) 3.14

Chimerism and donor-specific nonreactivity 27 to 29 years after kidney allotransplantation. Transplantation (1993) 3.13

Age-related osteogenic potential of mesenchymal stromal stem cells from human vertebral bone marrow. J Bone Miner Res (1999) 3.05

Biliary tract complications in human orthotopic liver transplantation. Transplantation (1987) 2.95

Islet isolation assessment in man and large animals. Acta Diabetol Lat (1991) 2.89

Experience in 1,000 liver transplants under cyclosporine-steroid therapy: a survival report. Transplant Proc (1988) 2.87

The use of FK-506 for small intestine allotransplantation. Inhibition of acute rejection and prevention of fatal graft-versus-host disease. Transplantation (1990) 2.79

THE IMMUNOSUPPRESSIVE EFFECTS OF FR 900506 IN RATS RECEIVING HETEROTOPIC CARDIAC ALLOGRAFTS. Surg Res Commun (1987) 2.75

Treatment of cyclosporin-induced haemolytic uraemic syndrome with FK506. Lancet (1990) 2.66

Effect of hepatic dysfunction and T tube clamping on FK 506 pharmacokinetics and trough concentrations. Transplant Proc (1990) 2.60

Suppression of allograft rejection with FK506. I. Prolonged cardiac and liver survival in rats following short-course therapy. Transplantation (1990) 2.59

Incidence and treatment of rejection episodes in primary orthotopic liver transplantation under FK 506. Transplant Proc (1991) 2.59

A randomized trial of primary liver transplantation under immunosuppression with FK 506 vs cyclosporine. Transplant Proc (1991) 2.49

Pharmacokinetics of FK 506: preclinical and clinical studies. Transplant Proc (1990) 2.48

Upper abdominal exenteration with liver replacement: a modification of the "cluster" procedure. Transplant Proc (1990) 2.40

Hepatotrophic effects of FK506 in dogs. Transplantation (1991) 2.39

Liver transplantation across ABO blood groups. Surgery (1986) 2.39

Toxicology of FK-506 in the Lewis rat. Transplant Proc (1987) 2.37

The antibody crossmatch in liver transplantation. Surgery (1986) 2.33

The incidence, timing, and management of biliary tract complications after orthotopic liver transplantation. Ann Surg (1994) 2.32

Clinical intestinal transplantation: new perspectives and immunologic considerations. J Am Coll Surg (1998) 2.31

The effects of FK 506 on renal function after liver transplantation. Transplant Proc (1990) 2.31

FK 506 in clinical kidney transplantation. Transplant Proc (1991) 2.29

Animal research in liver transplantation with special reference to the dog. Semin Liver Dis (1985) 2.28

The hepatotropic influence of cyclosporine. Surgery (1990) 2.27

Conversion of liver allograft recipients from cyclosporine to FK 506-based immunosuppression: benefits and pitfalls. Transplant Proc (1991) 2.26

Assessment of five-year experience with abdominal organ cluster transplantation. J Am Coll Surg (1995) 2.25

Evidence for superantigen involvement in insulin-dependent diabetes mellitus aetiology. Nature (1994) 2.25

Human islet isolation and allotransplantation in 22 consecutive cases. Transplantation (1992) 2.20

Three years clinical experience with intestinal transplantation. J Am Coll Surg (1994) 2.20

Induction of liver, heart, and multivisceral graft acceptance with a short course of FK 506. Transplant Proc (1990) 2.15

Graft-versus-host disease after brown Norway-to-Lewis and Lewis-to-Brown Norway rat intestinal transplantation under FK506. Transplantation (1993) 2.14

FK506 suppression of heart and liver allograft rejection. II: The induction of graft acceptance in rats. Transplantation (1990) 2.13

Potent induction immunotherapy promotes long-term insulin independence after islet transplantation in type 1 diabetes. Am J Transplant (2012) 2.12

Complications of venous reconstruction in human orthotopic liver transplantation. Ann Surg (1987) 2.11

The side effects of FK 506 in humans. Transplant Proc (1990) 2.08

Use of quantitative competitive PCR to measure Epstein-Barr virus genome load in the peripheral blood of pediatric transplant patients with lymphoproliferative disorders. J Clin Microbiol (1997) 2.05

Should the cement mantle around the femoral component be thick or thin? J Bone Joint Surg Br (2003) 2.05

Randomised trialomania? The multicentre liver transplant trials of tacrolimus. Lancet (1995) 2.04

A simple method of staining fresh and cultured islets. Transplantation (1988) 2.03

Shipment of human islets for transplantation. Am J Transplant (2007) 2.01

Augmentation of rat liver regeneration by FK 506 compared with cyclosporin. Lancet (1989) 2.01

Low flow venovenous bypasses in small dogs and pediatric patients undergoing replacement of the liver. Surg Gynecol Obstet (1986) 2.00

Treatment of hilar cholangiocarcinoma (Klatskin tumors) with hepatic resection or transplantation. J Am Coll Surg (1998) 1.99

Results of our first nine intraportal islet allografts in type 1, insulin-dependent diabetic patients. Transplantation (1991) 1.98

Pathology of human intestinal transplantation. Gastroenterology (1996) 1.98

FK 506 in steroid-resistant focal sclerosing glomerulonephritis of childhood. Lancet (1990) 1.94

Analysis of donor criteria for the prediction of outcome in clinical liver transplantation. Transplant Proc (1987) 1.90

Orthotopic liver transplantation for primary sclerosing cholangitis. Ann Surg (1988) 1.89

Lymphocyte traffic and graft-versus-host disease after fully allogeneic small bowel transplantation. Transplant Proc (1991) 1.89

Logistics and technique for combined hepatic-intestinal retrieval. Ann Surg (1992) 1.85

Improved human islet isolation using a new enzyme blend, liberase. Diabetes (1997) 1.84

The adverse impact on liver transplantation of using positive cytotoxic crossmatch donors. Transplantation (1992) 1.83

Endotoxaemia, pulmonary complications, and thrombocytopenia in liver transplantation. Lancet (1989) 1.82

Corrective treatment and anatomic considerations for laparoscopic cholecystectomy injuries. J Am Coll Surg (1994) 1.81

A human anti-CD40 monoclonal antibody, 4D11, for kidney transplantation in cynomolgus monkeys: induction and maintenance therapy. Am J Transplant (2009) 1.81

Pathologic observations in human allograft recipients treated with FK 506. Transplant Proc (1990) 1.80

Long-term survival and function of intrahepatic islet allografts in rhesus monkeys treated with humanized anti-CD154. Proc Natl Acad Sci U S A (1999) 1.79

The clinical impact of islet transplantation. Am J Transplant (2008) 1.78

Monitoring and treatment of intestinal allograft rejection in humans. Transplant Proc (1993) 1.78

Use of FK 506 in pediatric patients. Transplant Proc (1991) 1.77

Infections in adult liver transplant patients under FK 506 immunosuppression. Transplant Proc (1991) 1.75

Factors in the Development of Liver Transplantation. Transplant Proc (1985) 1.74